

Giannis Mountzios

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11900086/publications.pdf>

Version: 2024-02-01

35
papers

1,164
citations

304743

22
h-index

395702

33
g-index

35
all docs

35
docs citations

35
times ranked

2383
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 4185-4190. | 1.1 | 13 |
| 2 | Genotyping <i>KRAS</i> and <i>EGFR</i> Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 531-541. | 2.0 | 8 |
| 3 | The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. <i>Cancer Treatment Reviews</i> , 2018, 67, 34-44. | 7.7 | 71 |
| 4 | Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?. <i>Translational Lung Cancer Research</i> , 2018, 7, S179-S182. | 2.8 | 0 |
| 5 | Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. <i>Oncotarget</i> , 2018, 9, 11805-11815. | 1.8 | 9 |
| 6 | The emerging treatment landscape of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 138-138. | 1.7 | 29 |
| 7 | Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?. <i>Annals of Translational Medicine</i> , 2018, 6, 139-139. | 1.7 | 44 |
| 8 | Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 142-142. | 1.7 | 27 |
| 9 | Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy. <i>Translational Lung Cancer Research</i> , 2016, 5, 588-598. | 2.8 | 28 |
| 10 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097. | 4.5 | 82 |
| 11 | Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. <i>Molecular and Clinical Oncology</i> , 2016, 4, 211-220. | 1.0 | 11 |
| 12 | A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. <i>Immunotherapy</i> , 2016, 8, 1011-1019. | 2.0 | 34 |
| 13 | Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564. | 2.4 | 8 |
| 14 | The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2016, 8, 479-488. | 2.0 | 136 |
| 15 | Novel therapies for advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2016, 12, 659-667. | 2.4 | 11 |
| 16 | Future perspectives in cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 273-273. | 1.7 | 29 |
| 17 | Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 598-604. | 7.7 | 46 |
| 18 | Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece. <i>Journal of Geriatric Oncology</i> , 2015, 6, 111-118. | 1.0 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy. <i>World Journal of Clinical Oncology</i> , 2015, 6, 7. | 2.3 | 28 |
| 20 | Immunotherapy and lung cancer: current developments and novel targeted therapies. <i>Immunotherapy</i> , 2014, 6, 1221-1235. | 2.0 | 44 |
| 21 | The Case of the Missed Chest Radiograph: Bilateral Mammary Gland Metastases Mimicking Multifocal Primary Breast Cancer as the Initial Manifestation of Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1729-1731. | 1.1 | 0 |
| 22 | Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e91407. | 2.5 | 15 |
| 23 | Developments in the systemic treatment of metastatic cervical cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 430-443. | 7.7 | 34 |
| 24 | Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents. <i>Obstetrics and Gynecology International</i> , 2013, 2013, 1-8. | 1.3 | 7 |
| 25 | Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression and Survival in Operable Squamous-Cell Laryngeal Cancer. <i>PLoS ONE</i> , 2013, 8, e54048. | 2.5 | 39 |
| 26 | Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. <i>Lung Cancer</i> , 2012, 77, 146-150. | 2.0 | 34 |
| 27 | A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer. <i>Drug Safety</i> , 2011, 34, 175-186. | 3.2 | 9 |
| 28 | All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. <i>Cancer Treatment Reviews</i> , 2011, 37, 221-233. | 7.7 | 45 |
| 29 | Prognostic Significance of Bone Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published Data. <i>Clinical Lung Cancer</i> , 2011, 12, 341-349. | 2.6 | 35 |
| 30 | Developments in the systemic treatment of endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 278-292. | 4.4 | 29 |
| 31 | Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 94-109. | 4.4 | 38 |
| 32 | Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. <i>Translational Research</i> , 2010, 155, 247-255. | 5.0 | 29 |
| 33 | Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 610-618. | 4.3 | 22 |
| 34 | ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2007, 13, 284-289. | 2.6 | 79 |
| 35 | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor- κ B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. <i>Acta Oncologica</i> , 2007, 46, 221-229. | 1.8 | 83 |